Pages

▼
Showing posts with label NOVARTIS. Show all posts
Showing posts with label NOVARTIS. Show all posts

Novartis receives two new FDA approvals

›
Novartis announced that the US Food and Drug Administration (FDA) has approved Cosentyx ® (secukinumab) for the treatment of two new indi...

Novartis announces efficacy of Cosentyx in ankylosing spondylitis patients

›
Novartis announced that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondyliti...

GSK completes divestment rights of ofatumumab to Novartis

›
GlaxoSmithKline Plc announced the completion of its transaction to divest its rights to ofatumumab for auto-immune indications to Novartis...

Novartis presents new data on advanced breast cancer

›
Novartis will present data that highlight advancements in targeted combination therapy research, and underscore the company's continued...

EU Approves Entresto

›
Novartis announced that the European Commission (EC) has approved Entresto TM  (sacubitril/valsartan) for the treatment of adult patients w...

Novartis presents new two year data for Cosentyx

›
Novartis announced new results for Cosentyx ® (secukinumab) showing no further progression in joint damage in 84% of patients with psori...

Entresto recommended by CHMP for EU approval

›
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Entresto(TM) (sacubitr...

Novartis receives EU approval for Farydak

›
Novartis announced today that the European Commission has approved Farydak ® (panobinostat, previously known as LBH589) capsules, in co...

Novartis receives EU approval for new Revolade

›
Novartis announced today that the European Commission has approved Revolade ® (eltrombopag) for the treatment of adults with severe aplasti...